Cargando…

Body Composition of Transgender Women After Long-Term Hormone Therapy - a Cross-Sectional Study

Introduction: Few studies of transgender women (TW) body composition (BC) in long-term gender-affirming hormone therapy (GAHT) have been reported. Objective: To evaluate BC parameters of TW in long-term GAHT. Methods: A cross-sectional study was carried out with 8 TW (average age of 34.0 yo ±4.8), 8...

Descripción completa

Detalles Bibliográficos
Autores principales: Alvares, Leonardo A M, Santos, Lívia M, Santos, Marcelo R, Souza, Francis R, Almeida, Victor P, Mendonca, Berenice Bilharinho, Costa, Elaine Maria Frade, Alves, Maria-Janieire N Nunes, Domenice, Sorahia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089559/
http://dx.doi.org/10.1210/jendso/bvab048.1603
_version_ 1783687067656519680
author Alvares, Leonardo A M
Santos, Lívia M
Santos, Marcelo R
Souza, Francis R
Almeida, Victor P
Mendonca, Berenice Bilharinho
Costa, Elaine Maria Frade
Alves, Maria-Janieire N Nunes
Domenice, Sorahia
author_facet Alvares, Leonardo A M
Santos, Lívia M
Santos, Marcelo R
Souza, Francis R
Almeida, Victor P
Mendonca, Berenice Bilharinho
Costa, Elaine Maria Frade
Alves, Maria-Janieire N Nunes
Domenice, Sorahia
author_sort Alvares, Leonardo A M
collection PubMed
description Introduction: Few studies of transgender women (TW) body composition (BC) in long-term gender-affirming hormone therapy (GAHT) have been reported. Objective: To evaluate BC parameters of TW in long-term GAHT. Methods: A cross-sectional study was carried out with 8 TW (average age of 34.0 yo ±4.8), 8 cisgender men (CM) and 8 cisgender women (CW) matched to age and body mass index (BMI). All TW were non-gonadectomized subjects and were in estrogen [(E); transdermal estradiol (n=2), oral estradiol (n=3) and conjugated estrogen (n=3)], plus cyproterone acetate (CA) (n=8) therapy in an average time of 15.6 ±8.7 years of treatment. Total testosterone (ng/dL) levels of TW, CW and CM were 83,5 (range 12,0-637,0), 20,5 (range 12,0-41,0) and 480,5 (range 264,0-843,0) at the time of the study, respectively. BC was assessed by InBody 720. Percentage of fat mass (%FM), skeletal muscle mass (SMM) were evaluated. Baumgartner Index was calculated. Results: Regards %FM, that of TW was lower than CW (29,59 ±7,56 vs 32,9 ±3,99; p=0,5394) and higher than CM (23,58 ± 6,44; p=0.1512). SMM of TW was 33.6% higher than that of CW (p<0.001) and 14,7% lower than that of CM (p=0,014). Baumgartner Index of CM group was 17.7% higher than TW group (p=0,001), which presented rates 20.3% higher than the CW (0,002). Discussion: BC changes in the first two years of GAHT in TW were consistent with loss of lean mass and gained fat mass associated with an increase of body weight. This profile was identified in adults and youth transgender after short-term hormone therapy. Conclusion: Our data shown a similar profile of short-term treatment, with a body composition intermediate between BMI-matched cisgender males and females. However, unlike young TW undergoing short-term GAHT, the parameters of BC in the TW using estrogens plus cyproterone acetate in the long term did not present %FM statistically different from CW and CM, in contrast to the lean mass that maintained significant differences in the long term.
format Online
Article
Text
id pubmed-8089559
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-80895592021-05-06 Body Composition of Transgender Women After Long-Term Hormone Therapy - a Cross-Sectional Study Alvares, Leonardo A M Santos, Lívia M Santos, Marcelo R Souza, Francis R Almeida, Victor P Mendonca, Berenice Bilharinho Costa, Elaine Maria Frade Alves, Maria-Janieire N Nunes Domenice, Sorahia J Endocr Soc Reproductive Endocrinology Introduction: Few studies of transgender women (TW) body composition (BC) in long-term gender-affirming hormone therapy (GAHT) have been reported. Objective: To evaluate BC parameters of TW in long-term GAHT. Methods: A cross-sectional study was carried out with 8 TW (average age of 34.0 yo ±4.8), 8 cisgender men (CM) and 8 cisgender women (CW) matched to age and body mass index (BMI). All TW were non-gonadectomized subjects and were in estrogen [(E); transdermal estradiol (n=2), oral estradiol (n=3) and conjugated estrogen (n=3)], plus cyproterone acetate (CA) (n=8) therapy in an average time of 15.6 ±8.7 years of treatment. Total testosterone (ng/dL) levels of TW, CW and CM were 83,5 (range 12,0-637,0), 20,5 (range 12,0-41,0) and 480,5 (range 264,0-843,0) at the time of the study, respectively. BC was assessed by InBody 720. Percentage of fat mass (%FM), skeletal muscle mass (SMM) were evaluated. Baumgartner Index was calculated. Results: Regards %FM, that of TW was lower than CW (29,59 ±7,56 vs 32,9 ±3,99; p=0,5394) and higher than CM (23,58 ± 6,44; p=0.1512). SMM of TW was 33.6% higher than that of CW (p<0.001) and 14,7% lower than that of CM (p=0,014). Baumgartner Index of CM group was 17.7% higher than TW group (p=0,001), which presented rates 20.3% higher than the CW (0,002). Discussion: BC changes in the first two years of GAHT in TW were consistent with loss of lean mass and gained fat mass associated with an increase of body weight. This profile was identified in adults and youth transgender after short-term hormone therapy. Conclusion: Our data shown a similar profile of short-term treatment, with a body composition intermediate between BMI-matched cisgender males and females. However, unlike young TW undergoing short-term GAHT, the parameters of BC in the TW using estrogens plus cyproterone acetate in the long term did not present %FM statistically different from CW and CM, in contrast to the lean mass that maintained significant differences in the long term. Oxford University Press 2021-05-03 /pmc/articles/PMC8089559/ http://dx.doi.org/10.1210/jendso/bvab048.1603 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Reproductive Endocrinology
Alvares, Leonardo A M
Santos, Lívia M
Santos, Marcelo R
Souza, Francis R
Almeida, Victor P
Mendonca, Berenice Bilharinho
Costa, Elaine Maria Frade
Alves, Maria-Janieire N Nunes
Domenice, Sorahia
Body Composition of Transgender Women After Long-Term Hormone Therapy - a Cross-Sectional Study
title Body Composition of Transgender Women After Long-Term Hormone Therapy - a Cross-Sectional Study
title_full Body Composition of Transgender Women After Long-Term Hormone Therapy - a Cross-Sectional Study
title_fullStr Body Composition of Transgender Women After Long-Term Hormone Therapy - a Cross-Sectional Study
title_full_unstemmed Body Composition of Transgender Women After Long-Term Hormone Therapy - a Cross-Sectional Study
title_short Body Composition of Transgender Women After Long-Term Hormone Therapy - a Cross-Sectional Study
title_sort body composition of transgender women after long-term hormone therapy - a cross-sectional study
topic Reproductive Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089559/
http://dx.doi.org/10.1210/jendso/bvab048.1603
work_keys_str_mv AT alvaresleonardoam bodycompositionoftransgenderwomenafterlongtermhormonetherapyacrosssectionalstudy
AT santosliviam bodycompositionoftransgenderwomenafterlongtermhormonetherapyacrosssectionalstudy
AT santosmarcelor bodycompositionoftransgenderwomenafterlongtermhormonetherapyacrosssectionalstudy
AT souzafrancisr bodycompositionoftransgenderwomenafterlongtermhormonetherapyacrosssectionalstudy
AT almeidavictorp bodycompositionoftransgenderwomenafterlongtermhormonetherapyacrosssectionalstudy
AT mendoncaberenicebilharinho bodycompositionoftransgenderwomenafterlongtermhormonetherapyacrosssectionalstudy
AT costaelainemariafrade bodycompositionoftransgenderwomenafterlongtermhormonetherapyacrosssectionalstudy
AT alvesmariajanieirennunes bodycompositionoftransgenderwomenafterlongtermhormonetherapyacrosssectionalstudy
AT domenicesorahia bodycompositionoftransgenderwomenafterlongtermhormonetherapyacrosssectionalstudy